Pharmacotherapy for Alzheimer's disease: progress and prospects.
The number of people with Alzheimer's disease has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is, therefore, a substantial and increasing need for effective pharmacotherapy. Increased understanding of disease pathophysiology has led to palliative treatments for both cognitive and non-cognitive changes in behaviour. This, together with the prospect of drugs that slow or perhaps even halt the course of the disease, raises hope that this devastating disorder will soon be more amenable to pharmacotherapy with new drugs that either ameliorate specific symptoms or alter the course of the disease.
Palmer
Alan M
AM
Pharmidex, 72 New Bond Street, W1S 1RR, London, UK. alan.palmer@pharmidex.com
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001519:Behavior / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D016874:Neurofibrillary Tangles / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal